PERSONALISED MEDICINE: FOCUSING ON CITIZENS’ HEALTH

Significant EU investments in research on personalised medicine to:

1. Drive healthcare innovation - Establish Europe as a global leader in healthcare industry and innovation, and create jobs and economic growth.
2. Cut healthcare costs - As future medical challenges and chronic diseases become more prevalent.
3. Avoid adverse reactions - 6% of acute hospital admissions are due to serious adverse reactions to medicines.
4. Promote better access to loans - Public-private partnerships to develop better and safer medicines between €7.5m - €75m through the InnovFin Infectious Diseases initiative.
5. Strengthen Europe’s healthcare industry - Create synergies.
6. Make the EU a stronger global player - Cooperate with Canada, China, Australia, US and others to implement objectives such as common guidelines and best practices.

Research and innovation investment in better health:

Personalised medicine integrates information from multiple sources to make healthcare smarter, better and more cost-efficient.

What is our strategy?

EU funding stimulates collaborations between researchers, health research funders, regions, countries, policymakers and other stakeholders.

Promote personalised health and care research:

- Develop a medical model using individuals' genotypes and phenotypes, for example molecular profiling, medical imaging, and lifestyle data.
- Empower patients and involve healthcare providers.

International engagements:

- Science diplomacy and global scientific collaboration.

Develop EU countries' health research and innovation strategies:

- Support European coordination in health and disease research.
- Create synergies.

More information:

https://ec.europa.eu/research/health/personalised

www.icpermed.eu

@EUScienceInnov

© European Union, 2017